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The fatty acid-binding proteins (FABPs) are 
abundant intracellular proteins expressed in 
almost all tissues. They exhibit high affinity 
binding of a single saturated or unsaturated 
long-chain fatty acid (LCFA; ≥14 carbons), 
with the exception of the liver FABP, which 
binds two fatty acids or other hydrophobic 
molecules. Despite only moderate amino acid 
sequence homology they have highly similar 
tertiary structures consisting of a 10-stranded 
anti-parallel β-barrel and N-terminal helix-
turn-helix motif. Research emerging in the last 
decade has suggested that the FABPs have 
tissue-specific functions that reflect tissue-
specific aspects of lipid and fatty acid 
metabolism. Proposed roles for the FABPs 
include the assimilation of dietary lipids in the 
intestine via targeting to specific metabolic 
pathways and biogenesis of chylomicrons; 
targeting of liver lipids to catabolic and 
anabolic pathways; the regulation of lipid 
storage and release, and lipid-mediated gene 
expression in adipose tissue and macrophages; 
fatty acid targeting to β-oxidation pathways in 
muscle, and the maintenance of phospholipid 
membranes in neural tissues. The regulation of 
these diverse processes is reflected by the 
expression of different and sometimes multiple 
FABPs in these tissues, and may be driven by 
protein-protein and protein-membrane 
interactions. 
 
The fatty acid-binding proteins (FABPs) are 
abundant intracellular proteins expressed in almost 
all tissues; nine separate genes for FABPs have 
been identified in mammals. FABPs were named 
after the tissue in which they were discovered or 
are prominently expressed. This nomenclature can 
be misleading since several FABPs are expressed 
in more than one tissue, and a numerical 
nomenclature for the various FABPs has been 
introduced (1-6). All FABPs exhibit high affinity 
binding of a single saturated or unsaturated long-
chain fatty acid (LCFA; ≥14 carbons), with the 
exception of liver FABP (LFABP, FABP1), which 
binds two fatty acids or other hydrophobic 
molecules. Binding affinities correlate directly 
with fatty acid hydrophobicity (1-6). These small 
proteins (~15 kDa) show only moderate amino 
acid sequence homology, ranging from 20%-70%, 
yet they have highly similar tertiary structures. All 
have in common a 10-stranded anti-parallel β-
barrel structure which is formed by two orthogonal 
five-stranded β-sheets (Figure 1). The ligand-
binding pocket is located inside the β-barrel, and is 
framed on one side by the N-terminal helix-turn-
helix motif, consisting of two short α-helices 
between the first two β-strands, that is thought to 
act as the major portal for LCFA entry and exit (1-
6).  
Why are there multiple FABPs, then, when all 
have a similar fold and all bind LCFA? Other 
classes of lipid-binding proteins are, typically, 
ubiquitously expressed from a single gene. As will 
be discussed below, recent research has suggested 
that the FABPs have individual functions in their 
specific tissues. While all FABPs are involved in 
fatty acid disposition, it is likely that the diverse 
nature of fatty acid function is reflected in the 
diversity of FABP expression in different tissues. 
These divergent functions may be driven, in part, 
by protein-protein and protein-membrane 
interactions that are tissue specific. This review 
Storch Thumser FABP minireview April 16 Page 2 
will present currently held hypotheses regarding 
the functions of FABPs in different tissues, 
evaluating the evidence obtained from culture 
cells, structure-function analyses, and gene 
knockout mice.  
 
Tissue specific FABP functions:  
 
Adipose tissue 
 
Adipose tissue has long been known as a key 
organ of energy homeostasis, being the major 
reservoir of stored calories in the form of 
triacylglycerol (TG). It has become increasingly 
apparent that adipose tissue is also an important 
endocrine organ, releasing many bioactive small 
molecules, including numerous cytokines involved 
in inflammation (7). Adipose tissue metabolism, 
therefore, has important effects on systemic energy 
metabolism and inflammatory processes. 
Adipocytes express very high levels of the 
adipocyte FABP (AFABP, FABP4) and very low 
levels of the skin-type FABP (KFABP, FABP5). 
Studies of AFABP support a role in both the TG 
storage and inflammatory functions of the adipose 
tissue. Ablation of AFABP expression results in 
marked compensatory upregulation of KFABP 
expression (1,2), and is accompanied by relatively 
minor metabolic alterations in the adipose tissue, 
with small or no effects on TG hydrolysis or lipid 
synthesis processes observed (1,2). In vitro, 
AFABP and KFABP display similar ligand 
specificity and similar mechanisms for the 
transport of fatty acids to membranes, and these 
functional similarities are likely to underlie the 
mild phenotype observed in AFABP null adipose 
tissue (1,2). Simultaneous deletion of both FABPs, 
however, reveals their importance in maintaining 
systemic energy balance, with double-null animals 
displaying a marked protection against the 
development of insulin resistance and the 
metabolic syndrome, and against a variety of 
inflammatory diseases (2).  
The molecular mechanisms by which AFABP 
and KFABP function in adipose tissue are 
emerging, and studies to date point to multiple 
areas of potential involvement. AFABP has been 
shown to interact with the hormone-sensitive 
lipase (HSL), with charged residues in the helix-
turn-helix domain of AFABP interacting with 
oppositely charged residues on HSL. While a role 
in stimulating lipolysis by relieving lipase end-
product inhibition was initially proposed, only the 
apo-AFABP was found to interact with HSL. 
Moreover, the AFABP-HSL complex is present in 
both cytosol, where HSL is inactive, and on the 
surface of lipid droplets, when the lipase is active 
(1).  
AFABP may also function in the adipocyte by 
regulating the fatty acid species abundance in 
plasma, thus impacting systemic metabolism. 
Higher levels of the low-abundance palmitoleate 
were reported in adipose tissue and plasma of 
AFABP/KFABP double-null mice, and incubation 
of cultured liver and muscle cells with 
palmitoleate, in comparison to the saturated 
palmitate (PA; C16:0), led to changes consistent 
with protection against insulin resistance(8). The 
mechanism of palmitoleate action, and a direct 
comparison of palmitoleate with oleate (OA; 
C18:1 ω9), remains to be investigated (1).  
AFABP may also function in adipose tissue at 
the level of gene transcription. Structure-function 
studies have shown that AFABP binding of 
specific ligands leads to subtle conformational 
changes in the helical domain that promote nuclear 
localization via importins, and subsequent binding 
to the nuclear transcription factor PPARγ. Nuclear 
localization and PPARγ interaction occur only for 
those ligands that activate PPARγ target gene 
transcription, while non-activating ligands, though 
still binding to AFABP, do not cause nuclear 
localization (2,9).  
 
Macrophages 
 
Unlike adipose tissue, differentiated 
macrophages express high levels of both AFABP 
and KFABP, and KFABP expression in the 
macrophage remains unchanged following AFABP 
ablation, suggesting that the two proteins are likely 
to have distinct functions in this tissue. 
Macrophage-specific knockdown of AFABP in the 
ApoE deficient mouse has been shown to offer 
dramatic protection against the development of 
diet-induced atherosclerosis, even though animals 
remain hypercholesterolemic (1,2).  
It is likely that alterations in inflammatory 
cytokine production underlie the beneficial effects 
of AFABP knockdown, and several mechanisms 
are under investigation. Recently it was 
demonstrated that macrophage inflammatory 
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responses leading to cytokine production via c-Jun 
N-terminal kinase (JNK) and activator protein-1 
(AP1) require AFABP, whose transcription is in 
turn mediated by JNK (10). AFABP has also been 
shown to be necessary for macrophage 
endoplasmic reticulum (ER) stress response to 
inflammatory signals including lipid accumulation 
(11). As mentioned above, KFABP as well as 
AFABP, has been shown to exhibit a subtle 
conformational change in the helical domain that 
reveals a cryptic nuclear localization signal upon 
binding of a PPAR-activating ligand, resulting in 
translocation and PPAR-mediated transcriptional 
activation (2,9). Direct interaction of AFABP with 
JAK2 has also been reported and, similar to HSL 
interaction in the adipocyte, involves charged 
residues in the AFABP helix-turn-helix domain 
and requires fatty acid binding. Functional 
consequences of this interaction are inferred from 
alterations in JAK2 (Janus-activated kinase 2) 
signaling in macrophages from AFABP-/-
/KFABP-/- mice (12).  
 
Muscle 
 
LCFA contribute a large portion of the energy 
required in cardiac muscle, in skeletal muscle at 
rest, and to varying degrees in skeletal muscle 
during exercise (13). The major FABP in muscle 
tissues is heart FABP (HFABP, FABP3).  
HFABP expression is up-regulated during 
cardiomyocyte differentiation and associated with 
the inhibition of cardiomyocyte proliferation. A 
marked decrease in PA oxidation was observed in 
HFABP null cardiac muscle, although β-oxidation 
capacity was not affected, suggesting that HFABP 
is required for LCFA transport to maintain 
efficient mitochondrial β-oxidation. HFABP 
ablation also causes a dramatic switch in cardiac 
fuel selection from LCFA to glucose, resulting in 
reduced tolerance to exercise and cardiac 
hypertrophy in older animals. HFABP null mice 
displayed alterations in both cardiac LCFA uptake 
and esterification into TG and phospholipids (PL) 
(5). Relative levels of PA were increased in the 
heart PL pool relative to the neutral lipid pool. 
While arachidonic acid (AA, C20:4 ω6) 
incorporation into both TG and PL was decreased, 
the phosphatidylinositol and phosphatidylserine 
pools were not affected, thus implying that 
HFABP plays a role in trafficking fatty acids into 
specific PL pools that may be linked to lipid-
mediated signal transduction (5). There were no 
compensatory increases in expression of other 
FABPs in HFABP-/- cardiomyocytes, indicating 
that HFABP function is unique in this cell type (5).  
The up-regulation of HFABP expression during 
skeletal muscle differentiation is correlated with 
increased utilization of LCFA for both β-oxidation 
and esterification (3,5). HFABP null mice showed 
a decrease in the rate of muscle fatty acid uptake, 
however the skeletal muscle had an increased 
mitochondrial density compared to wild-type and 
could therefore maintain efficient utilization of 
fatty acids (3,5). Unlike the dramatic increase in 
glucose oxidation in cardiac muscle, glucose 
oxidation can be either increased or inhibited in 
HFABP null soleus muscle depending on 
physiological conditions that may be related to the 
TG content of the muscle tissue, thus the effects of 
HFABP loss are not as acute in the skeletal as 
compared to cardiac muscle (3;5).  
The positive effects of HFABP on LCFA 
utilization have been proposed to occur at the 
substrate level, to enhance LCFA supply to β-
oxidation and lipid synthesis pathways; and also at 
the regulatory level, by interacting with 
allosterically modulated enzymes as well as 
transcription factors (5). Studies have shown that 
the HFABP α-helical domain is involved in the 
transfer of LCFA from HFABP to acidic 
membrane domains, in a process requiring 
transient collisional interactions between HFABP 
and membranes, and it has been suggested that 
similar interactions could take place between 
HFABP and acidic peptide domains to facilitate 
protein-protein interactions, as have been observed 
between HFABP and plasma-membrane LCFA 
transporters (6,13). HFABP may also interact with 
peroxisome proliferator-activated receptor α 
(PPARα), a nuclear receptor, to induce the 
expression of mitochondrial and peroxisomal β-
oxidation pathways (6,14).  
 
Nervous system  
 
Neural membrane PL containabundant long-
chain polyunsaturated fatty acids (PUFA) such as 
docosahexaenoic (DHA) and AA, as well as 
saturated PA, components that have been linked to 
brain development and function. In addition, fatty 
acids and their metabolites are involved in 
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intracellular signaling, neurotransmission, and the 
regulation of gene transcription. Given the 
multiplicity of cell types and of LCFA functions in 
the nervous system, it is perhaps not surprising that 
multiple FABPs are also found. The central 
nervous system (CNS) expresses HFABP in the 
adult brain, while brain FABP (BFABP, FABP7) 
and KFABP are detected mainly in the pre- and 
peri-natal brain, respectively, with lower levels of 
expression in the adult brain. In contrast, myelin 
FABP (MFABP, Myelin P2, FABP8) is only found 
in the peripheral nervous system (PNS) (15,16). 
The expression of these four different FABPs in 
nerve tissues, each with distinct spatio-temporal 
distributions, suggests that they differentially 
moderate the actions of LCFA on specialized brain 
functions (16).  
In human brain the concentration of HFABP is 
≥ 10 times higher than that of BFABP in each part 
of the brain (16,17), suggesting that HFABP 
expression may be associated with the 
maintenance of the differentiation status of adult 
brain cells (16,17). Studies with HFABP null mice 
have shown that HFABP expression is necessary 
to maintain the ω6/ω3 PUFA balance in adult brain 
cells through the uptake and utilization of AA, and 
that decreased HFABP expression lowers the 
incorporation of AA into brain phospholipids, in 
particular phosphatidylinositol. Thus, HFABP 
appears to play a role in directing AA to specific 
classes, as well as in maintaining the steady state 
levels of AA in these phospholipids (18). An 
imbalance in the ω6/ω3 ratio of brain membranes 
is thought to be a factor in the pathogenesis of 
several neurological and psychiatric disorders (19), 
and decreased HFABP expression is found in the 
brains of patients with Down syndrome and 
Alzheimer’s disease, providing indirect evidence 
of a connection between HFABP and neurological 
function (16). 
Neurogenesis includes three contiguous phases, 
namely proliferation, migration and differentiation, 
and maturation and integration of the precursor 
cells (20). The expression of BFABP is highest in 
the mid-term embryonic stages of development, 
and is associated with the proliferation of neural 
progenitor cells during early cortical development 
(16). BFABP-/- mice have been shown to promote 
neural differentiation (3,16). Therefore the up-
regulation of BFABP (and also KFABP) is likely 
related to the proliferation and initial 
differentiation of neural cells, rather than their 
maturation and integration (20). BFABP 
preferentially binds ω3 PUFA, e.g. DHA (16,21-
23). DHA is a major component of brain 
phosphatidylethanolamine and phosphatidylserine 
and is highly enriched in the PL of the synaptic 
plasma membrane and synaptic vesicles (16). An 
increase in BFABP expression is correlated with 
an increase in DHA utilization, and BFABP null 
mice display decreased DHA incorporation into 
phospholipids, with an increase in AA and PA 
incorporation (2,16). Interestingly, BFABP 
expression levels are increased in schizophrenia, 
bipolar disorder, and Down syndrome, and have 
been associated with increased anxiety and 
depression and altered emotional behavior 
(3,16,21); these disorders are proposed to be linked 
to ω3 PUFA deficiency via alterations in 
dopaminergic and serotonergic processes (19). 
BFABP has also been proposed to be involved in 
the stimulation Jak3 (Janus-activated kinase 3) and 
Stat5 (signal transducers and activators of 
transcription 5) and activation of the RXR nuclear 
receptor by increasing the levels of ω3 PUFA (16). 
Antibodies against BFABP block cultured 
glial/neuronal cell differentiation and outgrowth, 
which has been interpreted to indicate that BFABP 
is expressed on the cell surface where it can be 
involved in LCFA uptake, cell-cell interactions or 
protein-protein interactions with cell surface 
receptors (16). 
KFABP is expressed mainly at the late 
embryonic stages and its expression is upregulated 
during the differentiation of human embryonic 
stem cells into motor neurons or astrocytes, as well 
as in various pathological conditions, including 
peripheral nerve injury (16). Thus KFABP may be 
required for the mobilization of the LCFA 
substrates necessary for active synthesis of lipids 
and membranes in the processes of neurite 
outgrowth, axon development and neural cell 
regeneration (16). KFABP has similar affinities for 
a range of saturated and unsaturated long-chain 
fatty acids, such as PA, AA and DHA, and in 
PC12 cells neurite extension can be stimulated by 
the expression of KFABP and a simultaneous 
supply of AA and DHA, supporting a role in 
membrane biogenesis during neurite outgrowth 
and axon development (16). It has been proposed 
that KFABP exerts its cell- and tissue-specific 
roles via ligand binding and transport, as well as 
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ligand-specific interactions with PPARβ/δ 
(2,14,22). Indeed, KFABP has been shown to bind 
retinoic acid (RA) and deliver this lipid hormone 
to PPARβ/δ,  thus partitioning RA away from the 
classical retinoic acid receptor and leading to the 
transcription of genes related to cell survival rather 
than growth inhibition (22). 
MFABP is expressed exclusively in the PNS 
myelin sheath during development and is absent 
from the CNS (15). Proposed roles include the 
generation and maintenance of lipid composition 
of the myelin membranes (15,23). The detection of 
plasma antibodies to MFABP in Guillain-Barré 
syndrome have been proposed to be linked to 
demyelination (24), although a specific function 
for MFABP in demyelination has not been 
elucidated. MFABP is extrinsically associated with 
membranes in peripheral nerve (6), a characteristic 
that has also been shown in CNS for BFABP; it is 
therefore tempting to speculate that these two 
FABPs have similar functions in the CNS and 
PNS. 
 
Liver 
 
The liver is active in lipid anabolism as well as 
catabolism, being the major site of very low 
density lipoprotein biogenesis, cholesterol and bile 
acid synthesis and bile production, and fatty acid 
oxidative pathways. It nevertheless expresses only 
a single FABP at high level, the liver FABP 
(LFABP, FABP1). In the LFABP null mouse, 
furthermore, essentially no compensation with 
other FABPs is found. This singular expression in 
such a multifunctional organ may be related to the 
ligand binding properties of LFABP, which are 
unique in the protein family in that two rather than 
one LCFA is bound to LFABP, and, moreover, a 
variety of other small hydrophobic ligands have 
been shown to bind in its relatively large ligand-
binding pocket (1,2,4).  
A consistent finding in the LFABP-/-mice is 
defective fatty acid β-oxidation that is not due to 
diminished oxidative capacity or decreased 
expression of relevant genes, supporting the 
hypothesis that LFABP acts as a LCFA 
transporter, specifically targeting ligand to β-
oxidation pathways (5,25,26). Despite the decrease 
in LCFA oxidation, however, the LFABP null 
mouse does not develop hepatosteatosis following 
either a high fat diet or an overnight fast, as found 
for wild type controls, indicating protection against 
development of the metabolic syndrome, although 
others report an exacerbation of obesity (27). 
Recently, it was shown that LFABP null mice 
were highly susceptible to the development of 
cholesterol gallstones, with the effect likely 
secondary to increased liver cholesterol levels and 
increased enterohepatic bile acid pool size (28). 
LFABP may in part be exerting its functional 
effects via regulation of gene transcription. Several 
reports indicate direct interactions between 
LFABP and PPARα (14,33), a nuclear receptor 
involved in the induction of hepatic β-oxidation 
(29), and it has been suggested that LFABP is 
specifically delivering LCFA or perhaps other 
ligands to the nucleus. A number of studies have 
shown that a portion of hepatocyte LFABP is 
localized in the nucleus, and a redistribution of 
some LFABP from the nuclear interior to the 
nuclear envelope in isolated hepatocytes from 
LFABP-/- mice was recently reported (14,30). 
Unlike what has been shown for AFABP and 
KFABP, however, the LFABP helix-turn-helix 
domain does not appear to contain structural 
information promoting nuclear localization, thus 
the molecular basis for LFABP delivery of ligand 
to the nucleus, as well as the structural basis for 
the putative LFABP-PPARα association, remain to 
be determined. It was recently shown that 
PPARβ/δ may also be a LCFA-responsive 
transcription factor in liver (31); whether LFABP 
might interact similarly with PPARβ/δ is presently 
unknown.  
 
Intestine 
 
The small intestine is responsible for the 
assimilation of dietary lipid as well as the reuptake 
of bile acids via the enterohepatic circulation. 
Differentiated enterocytes of proximal small 
intestine express high levels of two FABPs, the 
liver-type LFABP as well as the intestine-specific 
form, intestinal FABP (IFABP, FABP2). In 
rodents, both are expressed at roughly equal levels 
although in humans, LFABP is more abundant. 
The distal small intestine expresses a third member 
of the FABP family, ileal bile acid binding protein 
(ILBP, FABP6) (1,2,4). There appears to be no 
compensatory upregulation of LFABP upon 
ablation of IFABP, nor vice versa, again indicating 
unique functional roles. However, LFABP null 
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mice display an increase in the mRNA levels of 
ILBP, which may be part of the mechanism 
underlying the increased bile acid pool size and 
increased gallstone susceptibility (28).  
A unique feature of LFABP in the intestine is 
its role in chylomicron biogenesis. Cell-free 
transport studies demonstrated that LFABP is 
necessary for the release of specific ER-generated 
vesicles containing nascent TG-rich chylomicrons, 
the so-called pre-chylomicron transport vesicles 
(PCTV). Budding of the PCTV, which 
subsequently fuse with Golgi membranes, is 
dependent on LFABP, which cannot be replaced 
by IFABP (32). Recently, the intestinal ER-derived 
PCTV budding machinery was shown to be a >600 
kDa complex containing not only LFABP but also 
VAMP7, apoB48, CD36, and COPII proteins (33). 
As found in the liver, the LFABP null mouse 
also displays defective fatty acid β-oxidation in the 
intestine. Total mucosal oxidative capacity is not 
decreased, nor are there changes in the expression 
of genes involved in β-oxidation, thus in intestine 
as well as in liver, LFABP is likely playing a lipid 
transport/targeting role.  
Certain unique roles for the two proximal 
enterocyte FABPs in intracellular lipid metabolism 
have also been found. LFABP ablation does not 
substantially alter the incorporation of radiolabeled 
LCFA into TG or PL, but radiolabeled 
monoacylglycerol (MG) metabolism is shifted 
toward greater TG incorporation in the LFABP-/- 
mucosa, suggesting that LFABP is involved in 
partitioning of MG toward PL biosynthesis. In 
contrast, IFABP null animals display no changes in 
MG metabolism, consistent with the lack of MG 
binding by IFABP, but rather display a reduced 
incorporation of OA into TG relative to PL, 
suggesting that IFABP is involved in partitioning 
of LCFA toward TG synthesis. The metabolic 
changes observed in both LFABP and IFABP null 
models appear to occur by a non-transcriptional 
mechanism, supporting the hypothesis that the 
enterocyte FABPs are specifically trafficking 
bound ligands to their respective metabolic fates in 
a targeted manner. 
As discussed above for LFABP, the actions of 
IFABP in the enterocyte may lead to systemic 
metabolic effects, although, as with LFABP, 
reports are not entirely consistent and underlying 
mechanisms not clear. IFABP null mice, under 
certain conditions related to age, gender, or diet, 
appear to be more prone to developing obesity, 
hypertriglyceridemia, and increased liver TG 
accumulation (34,35), characteristics of the 
metabolic syndrome (36). A potential role for 
IFABP in the development of the metabolic 
syndrome is also supported by a single nucleotide 
polymorphism in the IFABP gene that leads to the 
substitution of threonine for alanine at position 54. 
The Thr54 isoform binds LCFA with greater 
affinity, indicating that the elevated serum TG 
levels are not secondary to greater sequestration of 
LCFA in the enterocyte but rather may be related 
to the aforementioned specific role of IFABP in 
intestinal TG synthesis and/or transport (1,2,4).  
 
Summary and Perspective 
 
The FABP family includes nine separate gene 
products, each with a unique tissue distribution. As 
the functions of fatty acids and other lipids are 
often highly tissue-specific, so it is becoming clear 
that the FABPs function in a tissue-specific 
manner as well. Thus, despite similar ligand 
binding characteristics and highly homologous 
tertiary structures, each FABP appears to have 
unique functions in specific tissues. Overall, the 
FABPs function as intracellular trafficking 
proteins, delivering or receiving LCFA and in 
some cases other small hydrophobic lipids to and 
from particular subcellular sites. The transport 
properties of the FABPs are governed in part by 
specific protein-protein and protein-membrane 
interactions, and the helix-turn-helix domain of the 
FABPs appears to specify these interactions. 
Several of the FABPs have been shown to deliver 
their ligands to nuclear transcription factors, 
thereby modulating gene expression in a tissue-
specific manner. Cellular changes in gene 
expression and lipid metabolism brought about by 
the FABPs leads to changes in whole body energy 
homeostasis. Given the role of aberrant lipid 
metabolism in most if not all of the metabolic 
syndrome disorders, the FABPs may be envisioned 
as central regulators of lipid disposition at the cell 
and tissue levels that have profound impact on 
systemic energy metabolism. 
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brain FABP, FABP7; CNS, central nervous system; DHA, docosahexaenoic acid, C22:6 ω3; FABP, fatty 
acid binding protein; HFABP, heart FABP, FABP3; IFABP, intestinal FABP, FABP2; ILBP, ileal bile 
acid binding protein, FABP6; KFABP, keratinocyte FABP, FABP5; LCFA, long chain fatty acid; LFABP, 
liver FABP, FABP1; MFABP, myelin FABP, FABP9; MG, monoacylglycerol; OA, oleic acid, C18:1 ω9; 
PA, palmitic acid, C16:0; PL, phospholipid; PNS, peripheral nervous system; PPAR, peroxisome 
proliferator-activated receptor; PUFA, polyunsaturated fatty acid; RA, retinoic acid; TG, triacylglycerol. 
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FIGURE LEGENDS 
 
Fig. 1. The crystal structure of human heart FABP (HFABP) containing an oleic acid ligand (1HMS.pdb). 
The protein structure is similar for all the FABPs and shows the β-barrel domain and the N-terminal helix-
turn-helix motif (37). 
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